Skip to content

US · BYSI · BIOTECHNOLOGY

BeyondSpring Inc. (BYSI) intrinsic value and stock valuation

$0.33as of 2026-11-21 · Mkt cap 35.77M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

BeyondSpring Inc. DCF and intrinsic value

InvestorsCraft values BYSI with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from BYSI’s statements →

BeyondSpring Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Florham Park, NY 07932 beyondspringpharma.com

How the business is doing

Fiscal 2014–2025, USD

Revenue
$0.00
20142025
Net income
-$-7.99M
20142025
Free cash flow
-$-20.07M
20142025
Total equity
-$-23.99M
20142025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2014–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$1.35M$1.35M
Operating income-$-8.95M-$-8.75M-$-15.08M-$-37.24M-$-66.24M
Net income-$-7.99M-$-11.12M-$-21.03M-$-33.28M-$-64.18M
EPSd-$-197.72K-$-279.89K-$-539.23K-$-851.37K-$-1.64M
Operating cash flow-$-20.02M-$-16.44M-$-16.47M-$-28.15M-$-47.24M
Capital expenditure-$-50K-$-220K-$-100K-$-30K-$-2.84M
Free cash flow-$-20.07M-$-16.67M-$-16.57M-$-28.18M-$-50.09M
Total assets$25.9M$34.3M$24.8M$46.2M$81.7M
Total debt$320K$590K$850K$4.96M$3.58M
Net debt-$-7.47M-$-2.33M-$-14.49M-$-29.43M-$-38.05M
Total equity-$-23.99M-$-14.29M-$-23.46M-$-3.01M$20.9M
Cash and short-term investments$12.6M$2.92M$15.3M$37.3M$72.4M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$1.35M$1.35M
Cost of revenue$90K$0.00$300K$0.00$0.00
Gross profit-$-90K$0.00-$-300K$1.35M$1.35M
Research and development expenses$4.39M$2.64M$7.27M$25.6M$36.9M
Selling, general and administrative expenses$4.56M$6.11M$7.51M$13M$30.7M
Other expenses-$-90K$0.00$0.00$0.00$0.00
Operating expenses$8.86M$8.75M$14.8M$38.6M$67.6M
Cost and expenses$8.95M$8.75M$15.1M$38.6M$67.6M
Interest income$80K$60K$420K$200K$100K
Interest expense$0.00$0.00$0.00$20K$90K
Depreciation and amortization$90K$280K$300K$1.14M$60K
Ebitda-$-8.54M-$-8.48M-$-13.62M-$-34.96M-$-64.49M
Operating income-$-8.95M-$-8.75M-$-15.08M-$-37.24M-$-66.24M
Total other income/expenses, net$320K-$-10K$1.16M$1.12M$1.6M
Income before tax-$-8.62M-$-8.77M-$-13.92M-$-36.12M-$-64.64M
Income tax expense$90K$100K$90K$160K$3.57M
Net income-$-7.99M-$-11.12M-$-21.03M-$-33.28M-$-64.18M
Weighted average shares outstanding$40.4M$39.7M$39M$39.1M$39M
Weighted average diluted shares outstanding$40.4M$39.7M$39M$39.1M$39M
Balance sheet
20252024202320222021
Cash and short-term investments$12.6M$2.92M$15.3M$37.3M$72.4M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$20.9M$28.6M$18.4M$38.5M$75.1M
Property, plant and equipment, net$470K$750K$1.05M$7.35M$4.95M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$5.05M$5.74M$6.39M$7.7M$6.53M
Total assets$25.9M$34.3M$24.8M$46.2M$81.7M
Accounts payable$360K$290K$560K$1.08M$1.66M
Short-term debt$320K$280K$260K$970K$2.11M
Deferred revenue$0.00$27.4M$1.75M$1.35M$1.37M
Total current liabilities$13.6M$11M$7.96M$7.35M$15.2M
Long-term debt$0.00$310K$590K$4M$1.47M
Deferred revenue, non-current$28.6M$27.4M$28.2M$34.2M$37.9M
Total non-current liabilities$36.4M$37.6M$40.3M$41.9M$45.6M
Capital lease obligations$320K$590K$590K$4.96M$2.01M
Total liabilities$49.9M$48.6M$48.3M$49.2M$60.7M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-408.43M-$-407.43M-$-396.3M-$-375.28M-$-342M
Accumulated other comprehensive income (loss)$600K$1.34M$890K$440K-$-520K
Total equity-$-23.99M-$-14.29M-$-23.46M-$-3.01M$20.9M
Total investments$4.78M$0.00$0.00$2.87M$30.7M
Total debt$320K$590K$850K$4.96M$3.58M
Net debt-$-7.47M-$-2.33M-$-14.49M-$-29.43M-$-38.05M
Cash flow statement
20252024202320222021
Net income-$-8.47M-$-11.12M-$-21.03M-$-36.28M-$-68.21M
Depreciation and amortization$90K$280K$300K$230K$60K
Stock-based compensation$0.00$2.06M$550K$1.67M$3.15M
Change in working capital-$-380K-$-1.38M$2.71M$6.41M$18.4M
Accounts receivable$0.00$0.00$0.00$0.00-$-1.77M
Inventory-$-20K-$-20K$190K$0.00$1.77M
Accounts payable-$-80K$0.00$0.00-$-570K-$-560K
Net cash provided by operating activities-$-20.02M-$-16.44M-$-16.47M-$-28.15M-$-47.24M
Investments in property, plant and equipment-$-50K-$-220K-$-100K-$-30K-$-2.84M
Acquisitions, net$10.1M$0.00$0.00$0.00$20.4M
Net cash used for investing activities$13.5M-$-12.01M-$-100K$18.3M-$-20.41M
Common stock issued$1.99M$0.00$0.00$0.00$40K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$2.27M$26.8M$0.00$3.43M$0.00
Net change in cash$4.86M-$-1.7M-$-16.65M-$-7.23M-$-67.91M
Cash at end of period$7.79M$16.1M$17.8M$34.4M$41.6M
Operating cash flow-$-20.02M-$-16.44M-$-16.47M-$-28.15M-$-47.24M
Capital expenditure-$-50K-$-220K-$-100K-$-30K-$-2.84M
Free cash flow-$-20.07M-$-16.67M-$-16.57M-$-28.18M-$-50.09M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About BeyondSpring Inc.

        BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.

        CEO
        Qiu Min
        Employees
        44
        Beta
        0.42

        Explore

        Frequently asked questions

        What is the intrinsic value of BeyondSpring Inc. (BYSI)?

        InvestorsCraft does not currently publish an intrinsic value for BYSI. How the IC value is calculated.

        Is BYSI undervalued?

        InvestorsCraft does not publish an undervaluation signal for BYSI at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.